Genprex's Reqorsa combo shows encouraging activity in lung cancer, shares up 3%

S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

Genprex's Reqorsa combo shows encouraging activity in lung cancer, shares up 3%

To read the full story on Seeking Alpha, click here.

Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Genprex Charts.

Genprex (NASDAQ:GNPX)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Genprex Charts.

Genprex Inc News

Genprex to Present and Participate at Upcoming May Investor and Industry Conferences
Wednesday 1 May 2024 (2 days ago) • PR Newswire (US)

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Tuesday 9 April 2024 (3 weeks ago) • PR Newswire (US)

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Wednesday 3 April 2024 (1 month ago) • PR Newswire (US)

Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
Tuesday 2 April 2024 (1 month ago) • PR Newswire (US)

Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Friday 22 March 2024 (1 month ago) • PR Newswire (US)

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Tuesday 19 March 2024 (1 month ago) • PR Newswire (US)

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Tuesday 19 March 2024 (1 month ago) • PR Newswire (US)

Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
Tuesday 12 March 2024 (2 months ago) • PR Newswire (US)

Form 8-K - Current report
Wednesday 6 March 2024 (2 months ago) • Edgar (US Regulatory)

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Wednesday 6 March 2024 (2 months ago) • PR Newswire (US)

Form 8-K - Current report
Monday 26 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 21 February 2024 (2 months ago) • Edgar (US Regulatory)

More Genprex Inc News Articles

RespireRx Pharmaceuticals (PK)

Global Developments (PK)

Voip Pal Com (QB)

MicroCloud Hologram

Bell Buckle (PK)

Globestar Therapeutics (PK)

Brookmount Explorations (PK)

NaturalShrimp (QB)

Moon Equity (PK)

BlackStar Enterprise (PK)

Yuenglings Ice Cream (PK)

Elite Pharmaceuticals (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions